10-K: Verano Secures $195M Term Loan, Refinances Debt

Verano Holdings Corp. has secured a new $195 million senior secured term loan and expanded its revolving credit facility to $100 million, refinancing its existing debt and providing capital for general corporate purposes.

Summary

• Verano Holdings Corp. secured a new $195 million senior secured term loan dated March 11, 2026, with Needham Bank as Administrative Agent and Chicago Atlantic Financial Services, LLC as Co-Administrative Agent.
• The proceeds from the new term loan, along with a $50 million draw from an expanded revolving credit facility, were used to repay the outstanding $240.55 million under the previous 2022 Credit Agreement, incurring a prepayment premium of approximately $4.345 million.
• The new term loan requires monthly amortization payments of $875,000 starting April 2026, with the remaining principal due on March 11, 2029, and an option to extend to March 11, 2030.
• The revolving credit facility was increased from $75 million to $100 million, and its maturity date was extended from September 29, 2028, to February 28, 2029.
• For the fiscal year ended December 31, 2025, Verano reported revenues of $821.5 million, a 6.5% decrease from 2024, primarily due to price compression in established markets and an accounts receivable strategy in the wholesale segment.
• Net loss for 2025 improved to $(257.9) million from $(341.8) million in 2024, driven by lower comparative impairments and operating expenses, partially offset by higher income tax provision.
• The company recorded significant impairment charges in 2025, including $86.591 million for goodwill and $90.849 million for intangible assets.
• Medical-use sales comprised 53% and adult-use sales 47% of consolidated revenues in 2025.
• Capital expenditures for 2026 are projected to be between $30 million and $50 million.
• The company settled litigation with Vireo Growth Inc. on October 28, 2025, involving a $1 million cash payment and conveyance of a $9 million real estate parcel.
• The company completed its Continuance from British Columbia to Nevada on November 3, 2025.
• The U.S. President issued an Executive Order on December 18, 2025, directing federal agencies to expedite the rescheduling of cannabis from Schedule I to Schedule III, which could impact federal illegality and Section 280E tax considerations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed filing. While the company successfully refinanced its debt and improved its net loss, revenue decline and significant impairment charges indicate ongoing operational challenges in a competitive and uncertain regulatory environment.

Positives

• Successful refinancing of existing debt with a new $195 million term loan and an expanded $100 million revolving credit facility, improving debt structure.
• Net loss improved significantly from $(341.8) million in 2024 to $(257.9) million in 2025, primarily due to lower impairment charges and operating expenses.
• Working capital increased by $104.849 million in 2025, indicating improved short-term liquidity.
• The company successfully settled a significant litigation with Vireo Growth Inc., resolving a claim for $860.9 million in damages for a $1 million cash payment and a $9 million property conveyance.
• The Executive Order to expedite cannabis rescheduling to Schedule III could potentially remove Section 280E tax considerations and lessen federal criminal penalties, which would be highly beneficial for the company's profitability.
• Management concluded that internal controls over financial reporting were effective as of December 31, 2025.

Negatives

• Revenues decreased by 6.5% to $821.5 million in 2025, primarily due to third-party price compression in established markets and the company's accounts receivable strategy in the wholesale segment.
• Gross profit margin slightly decreased from 50.5% in 2024 to 50.3% in 2025, driven by revenue decline and increased promotional activity.
• Provision for income taxes significantly increased by 118.6% to $91.678 million in 2025, despite a lower net loss, due to reduced tax benefits from impairment losses compared to the prior year.
• Significant impairment charges were recorded in 2025, totaling $86.591 million for goodwill and $90.849 million for intangible assets, indicating challenges in certain reporting units and asset values.
• The company maintains a substantial uncertain tax liability of $378.261 million as of December 31, 2025, related to its position on Section 280E of the Code.
• The new 2026 Credit Agreement includes a prepayment premium of 1.5% for the first two years, or if the maturity date is extended, which could increase costs for early repayment.
• The company's CEO, George Archos, participated as a lender in the new $195 million term loan, raising potential related-party transaction concerns.

Risks

• Cannabis remains illegal under U.S. federal law (Schedule I controlled substance), posing risks of federal enforcement, criminal penalties, substantial fines, and forfeiture, despite state-level legalization.
• The cannabis industry is subject to volatile political environments and evolving regulatory frameworks at federal, state, and local levels, which could slow or halt progress, repeal existing laws, or impose new restrictions.
• The federal rescheduling process for cannabis to Schedule III is subject to significant procedural delays and legal challenges, with no guarantee of timeline or beneficial outcomes, and would not federally legalize adult-use or state medical programs.
• Rescheduling to Schedule III could lower barriers to entry for well-capitalized institutional competitors (pharmaceutical, tobacco, CPG companies) with greater financial resources and federal regulatory experience.
• Disruptions in U.S. and global markets, inflation, rising interest rates, and declining consumer confidence could lead to decreased consumer spending, higher operating costs, and difficulty accessing financing.
• The company's secured debt facilities contain covenants (e.g., minimum cash balances, fixed charge coverage ratio) that restrict business activities, and failure to comply could lead to default, increased interest rates, or foreclosure on assets.
• The loss of executive officers or management team members experienced in the cannabis industry could negatively affect business operations due to difficulty in replacement and increased recruitment costs.
• Untested new products, competition from illicit and hemp-based markets, and potential product recalls due to defects, contamination, or inadequate labeling could damage brand identity and reduce sales.
• Risks of plant pathogens (e.g., Hop Latent Viroid) could materially affect yields, product quality, operating results, and lead to crop destruction, inventory write-downs, and supply shortfalls.
• Difficulty in accurately forecasting, managing, and monetizing inventory due to biological variability, inconsistent yields, regulatory testing, and demand fluctuations could result in excess, obsolete, or short inventory.
• Exposure to fraudulent or illegal activity by employees, contractors, and consultants could lead to financial losses, unauthorized information disclosure, and reputational damage.
• Challenges in integrating acquired businesses, facilities, systems, and personnel, as well as managing capacity constraints, could negatively impact business plans.
• Future research on cannabis efficacy and safety could lead to negative conclusions, potentially causing rollbacks in state regulations or adverse public perception, impacting demand for products.
• Property owned by cannabis industry participants could be subject to seizure and civil asset forfeiture by law enforcement due to federal illegality.
• As a holding company, Verano depends on the financial performance and distributions from its subsidiaries and affiliates, which are subject to operating results, laws, and contractual restrictions.
• Material acquisitions involve risks such as business disruptions, management distraction, increased financial leverage, and failure to realize anticipated benefits.
• The early-stage nature of the cannabis industry can lead to inadequate due diligence information, vulnerable cash management practices, and poorly documented transactions in acquisitions.
• Intense competition for suitable cultivation, production, and retail properties, coupled with local government restrictions and property owners' reluctance due to federal illegality, could increase acquisition/leasing costs.
• Acquiring businesses with limited representations and warranties from sellers may result in no or limited legal remedies for unknown problems.
• Entering or acquiring businesses in markets with uncertain or evolving cannabis regulations exposes the company to risks if final regulations differ from expectations.
• Limited industry and geographic diversification, particularly concentration in Florida (28% of sales), makes the business sensitive to local economic, regulatory, and competitive conditions, and natural disasters.
• Operating through joint ventures exposes the company to risks such as lack of control, disputes with partners, partner insolvency, and difficulty in exiting arrangements.
• Reliance on contractual arrangements with consolidated variable interest entities (VIEs) is less secure than direct ownership, potentially requiring substantial costs to enforce agreements if VIEs or their equity holders fail to perform.
• The pharmaceutical industry's development of synthetic cannabis products could reduce demand, volume, and profitability of organic cannabis products.
• Dependence on U.S.-based third-party suppliers, manufacturers, and contractors for key inputs (raw materials, utilities) creates risks of interruptions, quality issues, and increased costs due to supply chain disruptions or geopolitical events.
• New U.S. tariffs (e.g., 15% global import tariff under Section 122 of the Trade Act) and potential retaliatory tariffs could drastically increase costs for operational infrastructure and materials, delaying projects and impacting profitability.
• Inconsistent public opinion and perception of cannabis can hinder market growth and state adoption, and adverse scientific research or media attention could negatively impact demand.
• Cannabis cultivation is subject to agricultural risks like climate change, crop failure, pests, and diseases, which can impact yields and product quality.
• Cannabis cultivation and processing are energy-intensive, making the company vulnerable to rising or volatile energy costs and supply disruptions.
• Business premises are targets for theft, leading to potential human injury, financial losses (uninsured/underinsured), and federal enforcement if diversion occurs.
• Difficulty accessing or maintaining traditional banking services due to federal illegality of cannabis businesses, leading to reliance on cash and increased financial crime risk.
• Directors, officers, investors, and stakeholders may be required to disclose personal information to regulatory authorities, with non-compliance risking license revocation.
• If a stockholder is deemed unsuitable by a licensing authority, the company may be forced to redeem their ownership interests, diverting cash or incurring debt.
• Non-U.S. citizens involved with state-licensed cannabis businesses face risks of detention, denial of entry, or lifetime bans from the U.S.
• State laws restrict marketing and sales activities for cannabis products, limiting growth and market reach.
• Potential for increased regulation by the FDA or ATF, requiring compliance with new standards (e.g., GMP, clinical trials), which could be costly and impact operations.
• Federal illegality of cannabis may prevent the company from legally enforcing contracts or liens on cannabis assets in U.S. courts.
• Cannabis businesses may be denied U.S. federal bankruptcy protections, making restructuring difficult and increasing investment risk.
• Increasing use of AI could lead to operational disruptions, data inaccuracies, legal liabilities, and unintended disclosure of trade secrets if algorithms are flawed or data biased.
• Dependence on vendors for seed-to-sale tracking and POS systems poses risks of disruption, limiting ability to serve customers and operate profitably.
• Significant expenses may be incurred to promote and maintain brand identities in a competitive market, with no guarantee of success.
• Limited federal trademark protection for cannabis products and difficulty protecting trade secrets could negatively affect competitive position.
• Risk of infringement or misappropriation claims by third parties, leading to costly litigation and potential liabilities.
• Susceptibility to fraudulent activity (e.g., check fraud, phishing) leading to financial losses, data misuse, and reputational damage.
• Inability to fully realize anticipated benefits of the Continuance to Nevada (e.g., reduced administrative costs, corporate flexibility) due to unforeseen obstacles or legal complexities.
• Investment in Common Stock is speculative, with no guarantee of positive return, and carries a high degree of risk.
• Nevada law provides broader discretion and protection for directors and officers against personal liability, potentially discouraging claims for wrongful acts.
• Articles of incorporation and bylaws contain provisions that may prevent beneficial transactions for stockholders and insulate management from removal.
• Significant time and resources devoted to compliance with SEC, CSA, and Cboe regulations, increasing legal and financial costs.
• Risk of future deficiencies in internal controls over financial reporting, impairing financial statement accuracy and investor confidence.
• Potential dilution from future issuances of Common Stock or convertible securities for acquisitions, incentives, or financing.
• Sales of substantial amounts of Common Stock by existing holders could adversely affect market price and ability to raise capital.
• Common Stock may be subject to transfer restrictions, and their expiration could increase supply and depress market price.
• Market price of Common Stock is volatile and subject to fluctuations from various factors, including regulatory changes, economic performance, and competitor actions.
• Stockholders have little or no control over day-to-day business, investment decisions, or selection of licensees.
• Company does not expect to declare or pay dividends, and credit facilities restrict cash dividends.
• Certain stockholders (e.g., George Archos, Eminence Capital, LP) hold significant voting power, potentially impacting stockholder approvals and change of control transactions.
• IRS interpretation of Section 280E of the Code substantially limits deduction of business expenses for cannabis companies, leading to higher effective tax rates.

Future Outlook

The company anticipates continued growth in wholesale and retail operations by entering new markets and expanding in current ones, including when medical markets transition to adult-use. Growth plans involve applying for new licenses, acquiring existing licensed businesses, and maximizing operations under current licenses. Capital expenditures for 2026 are projected to be between $30 million and $50 million, supporting cultivation efficiency, retail expansion, store enhancements, and technology investments. The potential rescheduling of cannabis to Schedule III could remove Section 280E tax considerations and lessen federal criminal penalties, but the final effects and timeline are uncertain.

Management Comments

• Management believes the assumptions underlying the Company’s financial statements and accompanying notes are reasonable.
• The Company has taken a position that it may deduct ordinary and necessary business expenses and that such expenses are not limited to the application of Section 280E of the Code.
• Management performed an assessment of the effectiveness of our internal control over financial reporting at December 31, 2025, utilizing the criteria discussed in the Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on management's assessment, management has concluded that our internal controls over financial reporting were effective as of December 31, 2025.

Industry Context

StockSavvy.ai notes that the U.S. cannabis industry continues to navigate a complex and evolving regulatory landscape, with state-level legalization progressing while federal illegality persists. The recent Executive Order by President Trump to expedite cannabis rescheduling to Schedule III, if successful, could significantly alter the industry's financial and legal environment, potentially removing the burden of Section 280E taxation and reducing federal criminal penalties. However, this also introduces the risk of increased competition from well-capitalized institutional players. The industry faces ongoing challenges from price compression in established markets and competition from illicit and psychoactive hemp-based products, necessitating strategic operational optimization and brand differentiation.

Comparison to Industry Standards

• Verano's revenue decrease of 6.5% in 2025, driven by price compression, suggests it is facing similar market pressures as competitors like Green Thumb Industries Inc., Cresco Labs, Inc., Curaleaf Holdings, Inc., and Trulieve Cannabis Corp., which also operate in competitive multi-state cannabis markets.
• The improvement in net loss from $(341.8) million to $(257.9) million, despite revenue decline, indicates effective cost management and potentially lower impairment charges compared to prior periods, which could be a positive differentiator if competitors are still grappling with significant asset write-downs.
• The gross profit margin of 50.3% in 2025 is a key metric for comparison, as industry peers also strive for operational efficiencies in cultivation and processing to maintain margins amidst price compression.
• The company's strategy of vertical integration and geographic diversity across 13 states is consistent with leading multi-state operators aiming to mitigate risks associated with disparate state regulations and market fluctuations.
• The substantial uncertain tax liability related to Section 280E is a common challenge for all U.S. cannabis companies, and Verano's position on deducting ordinary business expenses reflects an industry-wide effort to challenge this federal tax burden.

Management Changes

Corporate Governance

Legal Proceedings

• Settlement of litigation with Vireo Growth Inc. on October 28, 2025. Vireo had sued for $860.9 million in damages. The settlement involved a $1 million cash payment from Verano and the conveyance of a real estate parcel with an unfinished cultivation facility valued at $9 million. A consent order dismissing all claims was entered on November 20, 2025.

Related Party Transactions

• George Archos, Chairman, CEO, and President, holds a 50% ownership interest in 740 Rte. 59, LLC and 783 Butterfield LLC, from which the company leases retail dispensary properties in Illinois. Payments to these entities were $184,000 and $371,000 respectively in 2025.
• GP Management Group, LLC, beneficially owned and controlled by George Archos, held a less than 1% ownership interest in Sweed High Tech Holdings, Inc., which provides point-of-sale software systems to the company. Payments to Sweed were $3,395,000 in 2025.
• George Archos, through an affiliated entity, funded $10,000,000 of the new $195,000,000 senior secured term loan, and will receive a pro rata share of interest and principal payments.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity issuances, but also benefits from improved debt structure and potential federal cannabis rescheduling. Price volatility and concentrated voting power by certain stockholders remain concerns.
• Lenders: New $195 million senior secured term loan and expanded $100 million revolving credit facility provide new investment opportunities and security interests in company assets.
• Employees: Continued employment, participation in benefit plans (including 401(k)), and eligibility for annual bonus and stock/cash incentive plans. Approximately 550 employees are covered by collective bargaining agreements.
• Customers: Continued access to medical and adult-use cannabis products across 13 states, with ongoing efforts in product development and retail experience. Potential for price changes due to market compression or increased costs.
• Suppliers/Vendors: Continued reliance on third-party suppliers for raw materials and services, subject to trade policy changes and potential cost increases.

Next Steps

• Make scheduled monthly amortization payments of $875,000 on the new $195 million term loan starting April 2026.
• Potentially elect to extend the maturity date of the new term loan to March 11, 2030, subject to lender consent and a 1.5% payment.
• Continue to draw on the expanded $100 million revolving credit facility as needed, with full repayment due February 28, 2029.
• Invest $30 million to $50 million in capital expenditures during 2026 for cultivation efficiency, retail expansion, store enhancements, and technology.
• Monitor and adapt to the ongoing federal rescheduling process for cannabis and potential changes to Section 280E tax considerations.
• Monitor and adapt to new U.S. trade policies, including the 15% global import tariff, and their impact on supply chain and costs.
• Continue to pursue geographic diversity and expansion in new and existing markets, including applying for new licenses and acquiring businesses.
• Provide joint status updates to the tribunal every ninety days regarding the stayed DEA rescheduling hearing.

Key Dates

Recommendation

The refinancing of debt and improved net loss are positive, but the revenue decline, significant impairment charges, and ongoing regulatory uncertainties in the cannabis industry, particularly regarding federal rescheduling and Section 280E, suggest a "hold" recommendation. The market is still highly volatile and competitive, and while there are potential upsides from federal policy changes, the immediate financial performance shows challenges.

Keywords

Cannabis, Marijuana, SEC Filing, 10-K, Verano Holdings Corp., VRNO, Term Loan, Revolving Credit, Debt Refinancing, Financial Results, Net Loss, Revenue, Impairment, Cannabis Regulation, Schedule III, Section 280E, Multi-State Operator, Cultivation, Retail, Wholesale, Financial Performance, Liquidity, Corporate Governance, Nevada, Needham Bank, Chicago Atlantic